Investigation of the Immunogenicity of Different Types of Aggregates of a Murine Monoclonal Antibody in Mice
- 15 August 2014
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (2) , 430-444
Abstract
The potential contribution of protein aggregates to the unwanted immunogenicity of protein pharmaceuticals is a major concern. In the present study a murine monoclonal antibody was utilized to study the immunogenicity of different types of aggregates in mice. Samples containing defined types of aggregates were prepared by processes such as stirring, agitation, exposure to ultraviolet (UV) light and exposure to elevated temperatures. Aggregates were analyzed by size-exclusion chromatography, light obscuration, turbidimetry, infrared (IR) spectroscopy and UV spectroscopy. Samples were separated into fractions based on aggregate size by asymmetrical flow field-flow fractionation or by centrifugation. Samples containing different types and sizes of aggregates were subsequently administered to C57BL/6 J and BALB/c mice, and serum was analyzed for the presence of anti-IgG1, anti-IgG2a, anti-IgG2b and anti-IgG3 antibodies. In addition, the pharmacokinetic profile of the murine antibody was investigated. In this study, samples containing high numbers of different types of aggregates were administered in order to challenge the in vivo system. The magnitude of immune response depends on the nature of the aggregates. The most immunogenic aggregates were of relatively large and insoluble nature, with perturbed, non-native structures. This study shows that not all protein drug aggregates are equally immunogenic.Keywords
This publication has 46 references indexed in Scilit:
- Immunogenicity of Therapeutic Proteins: The Use of Animal ModelsPharmaceutical Research, 2011
- Impact of Product-Related Factors on Immunogenicity of BiotherapeuticsJournal of Pharmaceutical Sciences, 2011
- Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic MicePharmaceutical Research, 2010
- Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human bodyJournal of Drug Targeting, 2010
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of AggregationJournal of Pharmaceutical Sciences, 2006
- T helper responses to Japanese encephalitis virus infection are dependent on the route of inoculation and the strain of mouse usedJournal of General Virology, 2003
- Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasiaCurrent Medical Research and Opinion, 2003
- Virally induced modulation of murine IgG antibody subclasses.Journal of Experimental Medicine, 1988
- Anaphylactoid reactions to infusions of plasma protein and human serum albumin Role of aggregated proteins and of stabilizers added during productionClinical & Experimental Allergy, 1979